YFNX has significant clinical effects, and its main active ingredient puerarin can protect against myocardial ischemia/reperfusion injury by inhibiting inflammation[10] and autophagy via the Akt signaling pathway,[20] increasing superoxide dismutase, decreasing creatine kinase and methylene dioxyamphetamine.[11] Therefore, we designed the systematic evaluation protocol by using the latest data to test the effectiveness and safety of YFNX in the treatment of CHD angina. The gene discussed is AKT1; the disease is myocardial ischemia.